TORRANCE, Calif., May 15, 2023 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX:EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the three months ended March 31, 2023.
Read more at prnewswire.comEmmaus Life Sciences Reports Q1 2023 Financial Results and Provides Business Update
PR Newswire - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here